Molecular docking of five colon cancer drugs with the erbb1 receptor

Colon cancer (CC) is the third most common type of cancer among women and men. Most causes of CC are due to age and lifestyle, with only a small number of cases due to underlying genetic disorders. Signs and symptoms of CC include blood in the stool, weight loss and altered bowel movements. Studies have shown that kinase tyrosine receptors play an important role in CC. Among these receptors, the epidermal growth factor receptor (EGFR) plays a more important role in tumorigenesis, tumor processes in colon cancer and activation of intracellular signaling pathways. Anti-EGFR drugs are used to reduce and treat the symptoms and symptoms of colon cancer, such as afatinib, brigatinib, dacomitinib, erlotinib and dasatinib. In this study, the binding energy of drugs to the EGFR receptor has been investigated by in silico studies. The receptor pdb sequence (G719S) was obtained from the protein Data Bank (PDB) and the three-dimensional pdb sequence of the drug was obtained using the drug bank server, then evaluated using Autodock software for binding energy and ligand efficiency between the drug and the receptor. The results revealed that erlotinib had a more stable binding to the receptor because the binding energy was lower than the other drugs mentioned.

Keywords:

Colon cancer , EGFR , Erlotinib , Autodock software